SEC Form 4 · accession 0001437749-17-010973
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Herm Rosenman
Director
Period of report
Jun 6, 2017
Accepted (ET)
Jun 8, 2017 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHARE OPTION (RIGHT TO BUY)F1 | $14.46 | Jun 6, 2017 | A | 7,457 | A | — | Jun 6, 2027 | ORDINARY SHARES | 7,457 | 7,457 | D |
Explanation of responses
- F1The option will vest and become exercisable as to 100% of the underlying shares on the date of the first annual meeting of the issuer's shareholders held after the date of grant.